SSA
OLMA icon

Schonfeld Strategic Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-113,978
Closed -$2.85M – 2537
2025
Q4 		$2.85M Buy
+113,978
New +$2.03M 0.01% 753
2025
Q2 		– Sell
-20,020
Closed -$75.3K – 2395
2025
Q1 		$75.3K Sell
20,020
-485,380
-96% -$2.44M ﹤0.01% 2047
2024
Q4 		$2.95M Buy
505,400
+43,474
+9% +$434K 0.02% 683
2024
Q3 		$5.52M Buy
461,926
+345,000
+295% +$4.41M 0.04% 510
2024
Q2 		$1.27M Sell
116,926
-86,899
-43% -$942K 0.01% 1103
2024
Q1 		$2.31M Buy
+203,825
New +$2.63M 0.02% 942
2023
Q4 		– Sell
-72,369
Closed -$894K – 2122
2023
Q3 		$894K Sell
72,369
-53,243
-42% -$543K 0.01% 1052
2023
Q2 		$1.13M Buy
+125,612
New +$758K 0.01% 931
2022
Q4 		– Sell
-14,700
Closed -$40K – 2888
2022
Q3 		$40K Sell
14,700
-17,200
-54% -$72.9K ﹤0.01% 2661
2022
Q2 		$130K Sell
31,900
-14,300
-31% -$45.4K ﹤0.01% 2068
2022
Q1 		$197K Buy
+46,200
New +$255K ﹤0.01% 1980

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Schonfeld Strategic Advisors's OLMA Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Olema Pharmaceuticals (OLMA) in Q1 2026, closing a stake of 113,978 shares — an estimated $2.85M sold.

Schonfeld Strategic Advisors first reported a position in OLMA in Q1 2022 and held it in 11 quarters. The position peaked at $5.52M in Q3 2024. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Olema Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 113,978 Olema Pharmaceuticals shares in Q1 2026, an estimated $2.85M.
  • Schonfeld Strategic Advisors first reported a position in Olema Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Schonfeld Strategic Advisors's Olema Pharmaceuticals position peaked at $5.52M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.